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Abstract
Cholesterol	pneumonia	or	endogenous	lipid	pneumonia	(ELP)	is	a rare	disease	that	can	occur	in	the	context	of	a systemic	disease	
or	following	a bronchial	obstruction.	It	is	characterized	by	a wide	range	of	diverse	symptoms	and	various	disease	course.	The	
present	report	introduces	a young	woman	diagnosed	with	adult	onset	still	disease	three	years	ago,	who	has	been	referred	with	
macrophage	activation	syndrome	(MAS).	She	underwent	biopsy	due	to	dyspnea	and	a crazy	paving	pattern	in	HRCT	of	the	lungs,	
leading	to	the	diagnosis	of	lipoid	pneumonia	based	on	the	interstitial	lymphocytic	inflammation	and	cholesterol	granulomas.	So	
far,	there	has	been	no	report	indicating	MAS	associated	with	cholesterol	pneumonia.	This	is	the	second	case	reporting	ELP	in	
the	adult	onset	still	disease.
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Introduction
Lipoid pneumonia or cholesterol pneumonia 
is caused by the accumulation of cholesterol in 
the lungs. Fat could enter the lungs exogenously 
through the mouth and nose, which is also called 
exogenous lipoid pneumonia, or could be accumu-
lated endogenously in the lungs [1]. It seems that 
the inability of macrophages to gather cholesterol 
collected in the alveoli due to the destruction of 
the type-II pneumocytes results in the endogenous 
accumulation of fat in the lungs [2]. The accumu-
lation of fat in the lung tissue causes fibroblastic 
inflammation of the interstitial lung tissue, which 
can lead to progressive dyspnea and, in some 
cases, respiratory failure. Notwithstanding the 
common exogenous lipoid pneumonia, the en-
dogenous type of this disease is rare, so that only 
a few cases have been reported thus far. 
Adult onset still disease (AOSD) is characte-
rized by the joints’ involvement associated with 
systemic symptoms, which is commonly found in 
adolescence. Although pulmonary involvement is 
not frequent in AOSD, pulmonary hypertension 
and pleuritis are known as the most common 
pulmonary involvements associated with this 
disease.
 In addition, a few cases of interstitial lung 
tissue involvement have been reported among 
these patients [3]. In this report, the described 
case is a patient with AOSD who developed cho-
lesterol pneumonia.
Case report
The patient was a 22-year-old, non-smoking 
woman, who had been receiving prednisolone 
and methotrexate treatments as soon as being 
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diagnosed with AOSD one year ago. She had 
been referred for a visit due to high fever, diar-
rhea, coughing, and dyspnea. She had fever as 
well as tachypnea and tachycardia during the 
examinations. The arterial oxygen saturation was 
89%, and the scattered petechial lesions could be 
observed on her thorax. The lung and abdomen 
examinations showed the end inspiratory crac-
kles in the lungs and mild organomegaly in the 
abdomen. The patient was diagnosed as pancy-
topenic by the laboratory tests, and also, the ESR 
was shown to be equal to 120. The CT scan of the 
lungs represented the diffuse bilateral perilym-
phatic nodularity view associated with interseptal 
thickening (crazy paving pattern) (Fig. 1). The 
woman underwent bronchoscopy. The bronchial 
washing was performed, and the specimens 
underwent microbial examination for microbes, 
tuberculosis and Pneumocystis carinii PCR, the 
results of which were all negative. Afterwards, 
the transbronchial lung biopsy was carried out, 
which showed no considerable results, except for 
a brief lymphocytic inflammation.
The patient initially underwent the treatment 
with broad-spectrum antibiotics and, then, since 
there was no fever break and lymphocytic hemo-
phagocytic syndrome was diagnosed, she received 
the pulse corticosteroid and endoxane treatments. 
As no improvement was observed in the systemic 
symptoms, etanercept was started for the patient. 
Six months later, despite the improved systemic 
symptoms, the dyspnea still continued. The 
spirometry exhibited a severe non-reversible obs-
truction view. Also, the previous results were still 
observed in the new CT chest images. Considering 
such condition, the patient underwent open lung 
wedge biopsy from the lower right-side lobe. The 
macroscopic view showed the lung stiffness, and 
stiff nodules inside it could be touched. In the 
microscopic view, prepared sections revealed 
inflammatory cell infiltration of the interstitium, 
mainly lymphocytes. There are intra-alveolar 
aggregation of inflammatory cells, granular ma-
terial and macrophage, prominent intra-alveolar, 
bronchiolar and scattered interstitial cholesterol 
clefts are noted (Fig. 2). The patient was diagno-
sed with lipoid pneumonia. Given that there was 
no response to the treatments, the woman was 
included in the lung transplant list. 
Discussion
The patient was a young woman with diagno-
sed AOSD, who had been receiving the treatments 
for three years. The lung biopsy led to the lipoid 
pneumonia diagnosis. Notwithstanding a  few 
reports on the pulmonary involvement in AOSD, 
the lipoid pneumonia involvement is yet very rare 
in this disease [4]. 
Lipoid pneumonia is divided into two types, 
namely exogenous and endogenous. In contrast 
to exogenous type that is quite common, the 
endogenous type, which is also known as cho-
lesterol pneumonia, is rare. In the pathology 
of these patients, in addition to the cholesterol 
granules inside the alveoli and interstitial tissue, 
lymphocytic inflammation of the interstitial 
tissue is also observed [5, 6]. Therefore, the pre-
viously used term “pulmonary interstitial and 
intra- alveolar cholesterol granuloma” (PICG) 
has been replaced with the terms “endoge-
nous lipoid pneumonia” (ELP) or “cholesterol 
pneumonitis”, which are currently used. There 
are a few reports of ELP among the rheumato-
logic patients [3, 6, 7]. 
Figure 1.	High-resolution	computed	tomography	scan	revealed	diffuse	
crazy	paving	appearance	in	mid,	and	lower	lobes	of	both	lungs	with	
ground	glass	opacity	and	coarse	interlobular	septal	thickening
Figure 2.	 In	 the	microscopic	view	 there	are	 lymphocytic	 interstitial	
and	intra	alveolar	infiltration	and	intra	alveolar,	bronchiolar	and	scat-
tered	interstitial	cholesterol	clefts
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Since only a few patients have been reported 
with diagnosed ELP, and also, these cases have 
been found in different conditions, the clinical 
course of the disease is still unknown. In some 
cases, the disease emerges as a mass, and the 
patient expresses only complaints of coughing. 
On the other hand, it may occur as a progres-
sive dyspnea caused by the development of 
the disease [1]. In the present case, the woman 
had a one-year progressive dyspnea. Given the 
underlying cause of the disease, the imaging 
results can also vary in ELP. In this study, the 
patient’s CT scan showed crazy paving. The most 
important findings include nodularity, alveolar 
opacity, and ground glass opacity [8]. In contrast 
to lipid exogenous pneumonia and fatty tumors, 
the lesion density in ELP is not fat density [1], 
the reason of which is probably fibrosis caused 
by fat accumulation. 
The best method for the diagnosis of ELP 
is the lung biopsy. Although the fat-containing 
macrophages can be observed in the bronchial 
lavage, yet there was no such finding for our 
patient. Besides, the biopsy specimen extracted 
from transbronchial lung biopsy in our patient 
was not diagnostic. Considering the advance-
ments in the new sampling methods, cryobiop-
sy can probably be an appropriate method for 
the diagnosis of this disease. All the treatment 
methods in this regard have been experimental 
and there is no confirmed treatment for ELP. 
Since many of the ELP cases occur in the context 
of another underlying disease, the treatment 
should be focused on that disease. The systemic 
corticosteroid, TNFa antagonist, intravenous 
immunoglobulins [IVIg], and complete lavage of 
the lungs are the methods that have been used 
for treatment to date [9–11]. If ELP emerges as 
a post-obstruction case, removing the obstruc-
tion or frequent lavage of the lungs will serve 
as the best treatment method [1]. In the cases 
in which the disease emerges as a mass and is 
diagnosed by biopsy, it is not certainly known 
whether the mass removal is necessary or not. 
However, in the cases of extensive disease, par-
ticularly when it is associated with systemic dis-
eases and the patient is symptomatic, prescrip-
tion of the immunosuppressive drugs has been 
proved to be successful in some instances [9]. 
The pulmonary involvement among the 
rheumatologic patients is also a drug side effect. 
Although our patient was receiving the treatment 
with methotrexate, ELP has not been reported 
to date as a side effect of this drug. In addition, 
discontinuing medication after 6 months had no 
consequence on the pulmonary lesions in our 
subject. Therefore, the use of methotrexate did not 
seem to be the cause of this complication in this 
case. As for our patient, the abnormal macrophage 
activity, which had led to MAS, could probably 
be associated with the incidence of ELP, but we 
could not perform the necessary investigations in 
this regard. Furthermore, the patient’s systemic 
complications were controlled by etanercept, but 
the pulmonary involvement is still continued, 
leading to the listing the patient as a candidate 
for the lung transplantation. 
Conclusion 
In the present study, a patient with AOSD 
who had chronic dyspnea due to ELP, was intro-
duced. Although many causes have been identi-
fied for dyspnea in rheumatologic diseases, ELP 
is not known as a common cause yet. According 
to this report, it is proposed to apply lung biopsy 
in the cases of the interstitial pulmonary involve-
ment with no identified cause in rheumatologic 
patients. 
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